SEC Form 4 · accession 0001209191-18-002542
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D Baird III
Officer — Chief Financial Officer
Period of report
Jan 3, 2018
Accepted (ET)
Jan 5, 2018 · 6:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 3, 2018 | A | 29,803 | $0.00 | A | 124,924 | D | |
| Common Stock | Jan 3, 2018 | F | 7,302 | $15.67 | D | 117,622 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $15.67 | Jan 3, 2018 | A | 43,075 | A | — | Jan 3, 2028 | Common Stock | 43,075 | 43,075 | D |
Explanation of responses
- F1These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 3, 2019. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2019, with the final installment vesting on January 1, 2022.